Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
indiana blog main
9
×
indiana top stories
life sciences
national blog main
9
×
boston blog main
clinical trials
eli lilly
boston top stories
fda
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
teva pharmaceutical
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
national
calcitonin gene-related peptide
chronic migraine
fremanezumab
migraine
migraine research foundation
novartis
bristol-myers squibb
cancer
What
approval
9
×
drug
fda
new
won
migraine
class
developed
eli
lilly
medicines
therapy
approved
bio
companies
decades
friday
late
oral
pain
roundup
starts
treat
acute
address
addresses
advanced
agency
aimmune
allergy
alnylam’s
amgen
announced
approves
arguments
awarded
bff
bid
big
biogen’s
Language
unset
Current search:
approval
×
" indiana blog main "
×
" national blog main "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines